Le Lézard
Classified in: Health, Science and technology
Subject: FDA

BD Receives U.S. FDA Approval for First Venous Stent to Treat Iliofemoral Venous Occlusive Disease

FRANKLIN LAKES, N.J., March 14, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration has granted premarket approval for the Venovotm venous stent, the first stent indicated to treat iliofemoral venous occlusive disease, which is obstructed or narrowed blood flow specific to the iliac and femoral veins located near the groin.

BD-Venovotm venous stent

The Venovotm venous stent is a flexible nitinol stent specifically designed to reopen blocked iliac and femoral veins in order to maintain adequate blood flow. The Venovotm venous stent is designed with a balance of radial strength, compression resistance and flexibility needed for the treatment of symptomatic post-thrombotic and non-thrombotic iliofemoral lesions. Additionally, the broad stent sizing allows clinicians to treat large diameter veins and long lesion lengths.

"The unique attributes of the Venovo stent make it particularly well-suited to treat iliofemoral occlusive disease," said Dr. Michael Dake, University of Arizona and the principal investigator for the Venovo IDE trial. "Most importantly, it is purpose-built for application in veins, and engineered to address the special challenges of venous lesions that are very different than those posed by arterial narrowing."

Iliofemoral venous occlusive disease occurs when there is impaired blood flow in the iliofemoral vein caused by acute or chronic deep-vein thrombosis, post-thrombotic syndrome, iliofemoral vein compression including May-Thurner Syndrome or a combination of these diseases.1 Symptoms include swelling of the legs, pain when standing, skin discoloration and ulcers.2 

One-year results from the prospective, multicenter single-arm VERNACULAR trial involving 170 subjects demonstrated the safety and effectiveness of the Venovotm venous stent for the treatment of symptomatic iliofemoral venous outflow obstruction. The clinical findings showed a weighted primary patency rate of 88.3 percent, with a 96.9 percent patency rate in non-thrombotic lesions and an 81.3 percent patency rate in post-thrombotic lesions at 12 months, exceeding the performance goal of 74 percent. In addition, patients treated with the Venovotm venous stent reported a statistically significant reduction in pain symptoms and improvement in quality of life (assessed by CIVIQ-20) at 12 months from baseline. The Venovotm venous stent was also deployed successfully to the target lesion and showed adequate coverage in all cases, and there were no fractures seen at 12 months.

"The FDA premarket approval of the Venovo venous stent represents a significant advance for interventionalists treating iliofemoral venous occlusive disease, an underrecognized condition," said Steve Williamson, worldwide president of Peripheral Intervention at BD. "We designed the Venovo venous stent in collaboration with clinicians to enable them to treat both post-thrombotic and non-thrombotic lesions. Clinicians will now have access to the broadest range of stent sizes in the U.S. for these difficult-to-treat lesions."

The Venovotm venous stent is commercially available in the U.S., Europe, Argentina, Australia, Brazil, Egypt, India, Israel, Mexico, Russia, Saudi Arabia, Singapore and Taiwan.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.

  1. Foley T, et al. (2015). Iliofemoral Deep Vein Thrombosis, Available online 24 November 2015.
  2. Al-Nouri O, Milner R. May-Thurner Syndrome, Vascular Disease Management 2011; 8(3).



Sandra Moskowitz

Monique N. Dolecki

BD Public Relations

BD Investor Relations






(PRNewsfoto/BD (Becton, Dickinson and Compa)

SOURCE BD (Becton, Dickinson and Company)

These press releases may also interest you

at 05:15
The "Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report by Treatment (Medication, Surgery), by End Use (Hospitals, Clinics), and Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering. The...

at 05:05
The global tonometer market size is anticipated to reach USD 483.6 million by 2026, according to a new report by Grand View Research, Inc., registering a CAGR of 5.3% over the forecast period. Rapidly increasing geriatric population and improving...

at 05:00
The Pharmaceutical Contract Development and Manufacturing Market is expected to reach USD 126.6 billion by 2024 from an estimated USD 90.0 billion in 2019, at a CAGR of 7.1%.  The Pharmaceutical Contract Development and Manufacturing Market report...

at 05:00
Employee benefit administration company, Clarity Benefit Solutions, explains the importance of educating employees about benefits. For many employees, choosing the proper benefits plan can be an overwhelming and daunting process, especially for...

at 04:35
The global rhinoplasty market size is expected to reach USD 5.4 billion by 2026, exhibiting a CAGR of 6.4% during the forecast period, according to a new report by Grand View Research, Inc. Factors such as rising awareness among people about physical...

at 04:05
Emergex Vaccines Holding Limited (?Emergex'), a biotechnology company developing set-point vaccines to prevent serious infectious diseases Emergex Vaccines Holding Limited (?Emergex'), a biotechnology company developing population-based synthetic...

News published on 14 march 2019 at 06:59 and distributed by: